Medline Inc. (MDLN) Stock Price & Analysis

Medline Inc. (MDLN) closed at USD 32 on Thursday, October 29, 2026, down 1.14% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 32.37; the Oct 29, 2026 session ranged USD 31.87–33.4 on volume of 15,888,069 shares. Market capitalization is $43.05B, with a 52-week range of USD 31.49–50.88 (NMS). Source: Nexqual, retrieved October 29, 2026 at 20:46 UTC.

Also available as compact Markdown for AI agents: nexqual.com/MDLN.md

Key facts (MDLN)

• Last four reported quarters (through Jun 27, 2026): revenue $28.6B, net income $1.03B (3.6% margin), free cash flow $1.59B (SEC filings).
• Valuation: P/E 42.0x, EV/EBITDA 17.4x, net debt $9.90B.
• Earnings quality: non-operating income -$807M vs operating income $2.03B over the last four quarters; P/E excluding non-operating income ≈25.2x (estimate: non-operating income taxed at the company's 15.5% effective rate).
• 4 of 80 tracked superinvestors hold MDLN (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 0 new, 1 added, 3 reduced, 0 unchanged.
• Analysts: Buy (mean 1.89 on a 1–5 scale) (27 analysts), mean target USD 44.31 (range 34–55).
• Total return with dividends: 1Y -21.9% vs S&P 500 +14.4%; 5Y -23.2% vs S&P 500 +79.1%.
• Next earnings: 2026-11-04, EPS estimate USD 0.35, revenue estimate $7.72B.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MDLN)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 27, 2026) (MDLN)

P/E 42.0x · P/E ex non-operating (est.) ≈25.2x · P/S 1.5x · EV/EBITDA 17.4x · EV/Sales 1.9x · P/FCF 27.1x · P/B 3.7x · FCF yield 3.70% · Earnings yield 2.38% · Buyback yield (TTM) 0.03% · Net debt $9.90B · EV $53.0B

Superinvestors (SEC 13F-HR, Q2 2026) (MDLN)

4 of 80 tracked investors hold MDLN (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Analysts (MDLN)

Consensus Buy (mean 1.89 on a 1–5 scale), 27 analysts; mean target USD 44.31 (low 34, high 55).

Rating changes, last 120 days:

Total return (dividends reinvested) (MDLN)

MDLN earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

MDLN recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

MDLN suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 25, 2026.

MDLN company outlook (results filed Aug 5, 2026)

• “The Company is updating its full year 2026 outlook for Organic Sales 2 growth to 9.0% to 10.0%, compared to its previous outlook of 8.5% to 9.5%, reflecting strong existing and new customer demand.”
• “The Company updated its Adjusted EBITDA 2 outlook to $3.3 billion to $3.4 billion, compared to its previous outlook of $3.5 to $3.6 billion, primarily reflecting higher than expected inflationary pressure from the Middle East conflict, increased operational investments to support customer demand, quality remediation efforts, and retail channel softness.”
• “The Organic Sales 2 reflects IEEPA tariff customer repayments and the Adjusted EBITDA 2 outlook does not reflect the benefit of IEEPA tariff refunds.”

Quoted word-for-word from the SEC 8-K results press release.

MDLN analyst estimates and revisions

MDLN options: expected move

Options price a move of about ±12.6% (±$4.10) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 3 reports the stock moved ±9.2% on average.

30-day implied volatility 55.8% vs 30.7% realized over the last 30 trading days. Put/call ratio (volume) 0.11. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 20:46 UTC)

Technical Analysis (MDLN)

Nexqual's technical model rates MDLN "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 20:46 UTC.

Analyst Ratings (MDLN)

Wall Street analysts rate MDLN "Buy" based on 27 analysts, with a mean price target of USD 44.31 (range USD 34–55), per Nexqual as of October 29, 2026 at 20:46 UTC.

Earnings (MDLN)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 20:46 UTC.

Financials & Fundamentals (MDLN)

Source: Nexqual, October 29, 2026 at 20:46 UTC.

Financial Health Score (MDLN)

Nexqual rates Medline Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 20:46 UTC.

Ownership (MDLN)

Source: Nexqual, October 29, 2026 at 20:46 UTC.

Leadership (MDLN)

Medline Inc. is led by James M. Boyle, CEO & Director, per Nexqual as of October 29, 2026 at 20:46 UTC.

Major Backers & Investors (MDLN)

Notable institutional backers of Medline Inc. include Carlyle Group Inc., Blackstone Inc, H&f Corporate Investors X, Ltd., according to Nexqual as of October 29, 2026 at 20:46 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 20:46 UTC.

From Medline Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• As of December 31, 2025, we offer approximately 145,000 med-surg products from over 1,300 third-party suppliers, including nearly all leading national brands, through our Supply Chain Solutions segment.
• For any new drug products regulated under the Federal Food, Drug, and Cosmetic Act such as our ReadyPrep CHG cloth, a sponsor must submit a New Drug Application ("NDA"), to the FDA for review and approval.
• At the state level in the United States, the CCPA added new privacy protections for California residents with respect to certain types of Personal Data, including by introducing new data privacy rights for California residents and establishing a regulatory agency dedicated to enforcing compliance.
• We have a large portfolio of intellectual property, including more than 2,300 granted patents as well as trademark registrations protecting our notable brands, including Medline, Curad, Microtek, Hudson, and Proxima.

Partnerships

• Violations are subject to civil monetary penalties of up to $124,732 (which is adjusted annually for inflation) for each violation, plus up to three times the remuneration involved, and may result in criminal fines and imprisonment of up to ten years, and/or exclusion from Medicare, Medicaid, or other governmental programs.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our business, results of operations, and financial condition both inside and outside the United States.
• Our products may also be subject to Import Alerts that restrict the importation of certain of our products or products manufactured by our suppliers into the United States.
• New environmental, health, and safety laws and regulations, violations of these laws or regulations, stricter enforcement of existing requirements, or the discovery of previously unknown contamination could result in increased costs and other burdens.
• The failure to comply with anti-corruption laws or trade restrictions, including economic sanctions, could materially adversely affect our business, results of operations, and financial condition and result in civil and/or criminal penalties.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:46 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt